View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 1, 2021

CureVac’s CVnCoV vaccine shows 48% efficacy in Phase IIb/III trial

The Phase IIb/III trial will continue to complete subjects’ follow-up assessments.

CureVac has reported data from the final analysis of Phase IIb/III HERALD clinical trial of its vaccine candidate, CVnCoV, which showed an overall efficacy of 48% against Covid-19 of any severity.

Last month, the company said that  CVnCoV failed to meet prespecified statistical success criteria, demonstrating a 47% efficacy at the 40,000-participant trial’s second interim analysis.

The latest data revealed significant protection among subjects aged 18 to 60 years, with a 53% efficacy against any disease severity and across all 15 identified strains, the company noted.

The vaccine also had a 77% efficacy against moderate to severe Covid-19 and provided complete protection against hospitalisation or death in this age group.

Among subjects aged above 60 years, who were 9% of the analysed cases, the trial findings did not allow a statistically significant efficacy determination.

CureVac noted that the final analysis’ statistical success criteria were met based on 228 cases, which occurred a minimum of two weeks from the second dose, including 68 more adjudicated cases versus the 160 cases pre-defined according to the study protocol.

The results are said to validate the favourable safety profile of the Covid-19 vaccine in all age groups.

Meanwhile, the company will continue the trial to conclude follow-up evaluations for participants. Available results were submitted to the European Medicines Agency.

CureVac CEO Dr Franz-Werner Haas said: “In the current context of an increasingly diverse environment of Covid-19 variants, and with very little residual prevalence of the original strain, we are confident that the HERALD study offers clinically relevant data regarding the effect of emerging variants on vaccine efficacy.”

A total of 228 adjudicated Covid-19 cases were evaluated in the final analysis. In subjects aged 18 to 60 years, strain-dependent efficacy of the vaccine was nearly 42% to up to 67%, across higher incidence strains.

Of the 228 cases, 204 were sequenced to detect the variant responsible for the infection and were included in the efficacy assessment.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena